Mediaboss Marketing

The European Union's proposed carbon pricing rules could hit a major snag in the form of China and the U.S., but one expert predicts it will still possible to convince the economic superpowers to get onboard using a series of cautious steps.

The EU said in July that it wants to impose a carbon border adjustment mechanism also referred to as CBAM. The measure, if approved, will force EU businesses to pay a carbon levy for goods they import from outside the bloc. In essence, it aims to incentivize other places with less stringent emissions rules to reduce their carbon footprints or else risk losing some business.

The problem is that some nations might not want to go down that route; or at least not as fast as the EU, which is aiming to cut its greenhouse gas emission by 55% from 1990 levels by the end of 2030. China, India, South Africa and Brazil said in April they had "grave concern" regarding the EU's intentions for a carbon tax, calling it "discriminatory."

Tim Gore, member of the Institute for European Environmental Policy, a think tank, told CNBC in July that the CBAM "has very big implications, of course, for countries which are exporting into the EU market."

As such, he said the EU will have "to invest in serious dialogue" with those countries to bring them on board. He said one of the ways to achieve this is "to make sure the revenues that will be generated are returned to those countries to support their low carbon transition." He said this would be particularly useful for poorer countries, that are looking to increase their cash positions.

But China is not necessarily in this category and nor is the United States, which has also raised eyebrows over the EU's plan. John Kerry, the U.S.' top climate envoy, said earlier this year he had concerns about the proposal and that it should be used only has a "last resort," suggesting that other steps could be taken to reduce global emissions.

Gore, from the Institute for European Environmental Policy, believes that competition to be the world's leading economy will be the solution to any conflict with the EU's climate plans.

"Both those economies [the U.S. and China] know as well that the EU here is making a serious down payment on advancing into this new low carbon economy. So irrespective of the international climate negotiations, those governments will be looking at their own economies and saying where is the competitive edge in the next 10 to 20 years," Gore said via Zoom, while adding that Beijing and Washington will want to make sure they will not be left behind in the race to carbon neutrality.

As long as industrial installations outside the EU are not subject to similarly ambitious measures, these efforts can lose their effect.

Paolo Gentiloni

European Commissioner

A Brussels-based think tank, Bruegel, also said in a blogpost last month that the EU should ensure that international talks over its carbon tax plan happen at the World Trade Organization. This approach would likely reduce future trade disputes in this space.

Either way, the EU seems intent in pursing this policy.

The European Commission, the executive arm of the EU, decided to put forward the CBAM proposal despite the concerns raised by some international partners. The institution believes the policy is essential to prevent "carbon leakage" the idea that companies operating in Europe would shift their production to places with less restrictive emissions policies.

A detail of the pilot carbon dioxide (CO2) capture plant is pictured at Amager Bakke waste incinerator in Copenhagen on June 24, 2021. - The goal is to be able to capture 500,000 tonnes of CO2 from Amager Bakke's emissions by 2025.

IDA GULDBAEK ARENTSEN | AFP | Getty Images

"As long as industrial installations outside the EU are not subject to similarly ambitious measures, these efforts can lose their effect," the EU's economic commissioner, Paolo Gentiloni, said in July about the need to impose the CBAM.

As a result, the 27 EU member states and the European Parliament are assessing the proposal. But this legislative process could take up to two years to be fully implemented into law.

"We are already too late in moving on climate change. We can see this summer,extreme weather events all around the world," Bob Ward, from the Centre for Climate Change Economics and Policy in London told CNBC last week.

He added that "this is going to continue to get worse for at least the next three decades till we get to net zero as a world."

"We need an orderly but accelerated transition towards net zero emissions," he said.

More:
How Europe could get China and the U.S. on its side with new carbon tax - CNBC

Several states from the European Union, including neighboring Poland, Estonia, and Lithuania, have accused Belarusian president Alexander Lukashenko of illegally sending migrants into the E.U. The group claims that Lukashenko is acting in retaliation to the blocs sanctions over the disputed Belarusian presidential election of 2020, making migrants his political tools and risking the creation of broad anti-migrant sentiment in the E.U.

During a news conference last Tuesday, German chancellor Angela Merkel accused Lukashenko of using refugees . . . from Iraq, in a hybrid way to undermine security. Radio Free Europe/Radio Liberty (R.F.E./R.L.), a U.S. government-funded international radio organization broadcasting from information-restricted countries, also reports that Lukashenko vowed to send drugs and migrants into [the EU] after the bloc imposed . . . sanctions [over a forced flight diversion to Minsk] to arrest an opposition blogger.

This problematic approach to sanctions only worsens the existing crisis. Using migrants as a political tool risks creating greater far-right sentiment in the E.U. and invites pushback from migrants that are unwillingly being used for political purposes. Also, many of the migrants are truly in need and do not want to be involved in the political standoff between Belarus and the E.U.

Belaruss greater role in the flow of migrants into the E.U. has seen far many more migrants crossing into European countries this year than in 2020. In Lithuania, for instance, Reuters reports that 4,124 people, many from Iraq, crossed into the country illegally in 2021. Lithuanian president Gitanas Nauseda signed a decree on August 13th calling for an army deployment to counter illegal crossings at the border, R.F.E./R.L. says. Poland has seen similar numbers and taken similar measures, deploying more than 900 troops to its border with Belarus as of last Wednesday.

The E.U. is concerned that the surge might signal a repeat of the 2015-16 migration crisis. During those years, Reuters writes, the arrival of more than a million people from the Middle East stretched security and welfare systems and fueled support for far-right groups. Without directly mentioning the recent Taliban takeover of Afghanistan, interior ministers from the E.U. said there was a need to strengthen the entire external border of the E.U. to prevent illegal crossings in the future. This hardline approach leaves migrants who will be in danger if they return home with few alternatives.

E.U. leadership should not be quick to enact strict border measures. Rather, it should analyze solutions to alleviate the large number of migrants on the Polish and Baltic state borders.

One such solution may be establishing migrant admission quotas across the bloc. Ylva Johansson, who oversees migration and asylum manners in the E.U.s executive Commission, called on member states on Wednesday to ramp up admission quotas for Afghans in need of protection, particularly for women and girls. European Parliament president David Sassoli has also proposed that the European Commission should take charge of equally relocating Afghan refugees following the Taliban takeover of their country.

While an admission quota solution is unlikely to resolve the surge of migrants, it would alleviate the situation in the eastern part of the bloc. Those migrants who arrive to Poland or Lithuania could then go to other E.U. countries, which may put less strain on Polish and Lithuanian institutions. However, countries like Poland and Hungary are opposed to such plans. These countries are unlikely to approve if the E.U. proposes an admission quota solution.

Regardless of where in the E.U. migrants end up, E.U. officials and institutions must ensure those people access to basic resources (including food, water, and a place to sleep), healthy conditions in shelters, and a transparent process for asylum seekers.

E.U. leadership should also refrain from hardline rhetoric that may encourage far right groups. Much of the blocs attitude to migrants is influenced by officials comments, which can welcome new arrivals or fuel opposition. Earlier this week, Polish deputy prime minister Piotr Gliski said his country defended itself against the wave of refugees in 2015 and now it will also defend itself. Far-right groups are quick to seize on these comments to continue anti-migrant sentiment around the block. E.U. officials messages should be used to reach solutions, rather than creating new problems.

Open dialogue with E.U. leadership is more likely to produce an agreeable outcome for both migrants and European countries. E.U. officials must not rely only on hardline approaches, but instead collaborate as a bloc to overcome logistical issues with admission quotas, process asylum applications, and create solutions to ensure that migrants can seek asylum.

Go here to see the original:
At-Risk Migrants: Political Tools In The European Union - The Organization for World Peace

"This is a significant milestone for AbbVie in our pursuit to transform care in atopic dermatitis," said Michael Severino, M.D., vice chairman and president, AbbVie."We are excited to provide an additional treatment option in Europeto help alleviate the burden of unrelenting itch and rash that many of these patients struggle with in daily life, despite available treatment options."

The EC approval is supported by data from one of the largest registrational Phase 3 programs in atopic dermatitis with more than 2,500 adults and adolescents with moderate to severe disease.1 These studies evaluated the efficacy and safety of RINVOQ monotherapy (Measure Up 1 [MU1] and Measure Up 2 [MU2]) and with topical corticosteroids (AD Up [AU]) compared to placebo.1 In all three studies, the co-primary endpoints were at least a 75 percent improvement in the Eczema Area and Severity Index (EASI 75) and validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) score of 0/1 (clear or almost clear) at week 16.1

"As a dermatologist researching and treating atopic dermatitis for more than 25 years, I've seen first-hand the debilitating impact this disease can have on a person's daily life," said Alan Irvine, M.D., D.Sc., professor of dermatology, Trinity College Dublin, Ireland, and RINVOQ clinical study investigator. "Clinicians need more tools to help them treat and manage this complex disease. The degree and early onset of skin clearance and itch relief in the RINVOQ Phase 3 clinical studies are very encouraging. The outcomes have the potential to advance treatment goals for patients with moderate to severe atopic dermatitis."

Highlights From the Global Phase 3 Atopic Dermatitis Clinical Trial Program1Across the Phase 3 studies, all primary and secondary endpointswere met with 15 mg and 30 mg doses of RINVOQ compared to placebo. Highlights include:

The most commonly reported adverse reactions (5% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection (25.4%), acne (15.1%), herpes simplex (8.4%), headache (6.3%) and increased blood creatine phosphokinase (CPK; 5.5%).1 The most common serious adverse reactions were serious infections (<1.0%).1

The Marketing Authorization means that RINVOQ is approved in all member states of the European Union, as well as Iceland, Liechtenstein, Norway and Northern Ireland. RINVOQ is already approved for the treatment of moderate to severe atopic dermatitis in Russia, Saudi Arabia, United Arab Emirates, New Zealand and Chile, and is currently under review in the U.S. by the Food and Drug Administration (FDA).

*10,500 patients includes all patients across all arms (active treatment and placebo) in 8 Phase 3 trials in rheumatoid arthritis, 2 in psoriatic arthritis, 1 in ankylosing spondylitis and 5 in atopic dermatitis.2-9 This includes 344 adolescent patients (aged 12 to 17 years) in the Phase 3 Measure Up 1, Measure Up 2 and, AD Up studies in atopic dermatitis.1,2,5 Of the total number of patients included in these trials, 6,280 were randomized to receive RINVOQ at either dose.2-9

About RINVOQ(upadacitinib)Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.1,10-20In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.1RINVOQ 15 mg is also approved by the U.S. Food and Drug Administration (FDA) for adults with moderately to severely active rheumatoid arthritis, and by the European Commission for adults with moderate to severe active rheumatoid arthritis, adults with active psoriatic arthritis (PsA) and adults with active ankylosing spondylitis (AS). Phase 3 trials of RINVOQ in rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.12-20

Important EU Indications and Safety Information about RINVOQ(upadacitinib)1

Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Ankylosing spondylitisRINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

ContraindicationsRINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.

Special warnings and precautions for useImmunosuppressive medicinal productsUse in combination with other potent immunosuppressants is not recommended.

Serious infectionsSerious and sometimes fatal infections have been reported in patients receiving upadacitinib. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis have been reported. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis have been reported with upadacitinib. As there is a higher incidence of infections in patients 65 years of age, caution should be used when treating this population.

Viral reactivationViral reactivation, including cases of herpes zoster, was reported in clinical studies. The risk of herpes zoster appears to be higher in Japanese patients treated with upadacitinib.

VaccinationsThe use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating upadacitinib, in agreement with current immunization guidelines.

MalignancyThe risk of malignancies, including lymphoma is increased in patients with rheumatoid arthritis (RA). Malignancies, including nonmelanoma skin cancer (NMSC), have been reported in patients treated with upadacitinib. Consider the risks and benefits of upadacitinib treatment prior to initiating therapy in patients with a known malignancy other than a successfully treated NMSC or when considering continuing upadacitinib therapy in patients who develop a malignancy.

Hematological abnormalitiesTreatment should not be initiated, or should be temporarily interrupted, in patients with hematological abnormalities observed during routine patient management.

Cardiovascular riskRA patients have an increased risk for cardiovascular disorders. Patients treated with upadacitinib should have risk factors (e.g., hypertension, hyperlipidemia) managed as part of usual standard of care.

LipidsUpadacitinib treatment was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.

Hepatic transaminase elevationsTreatment with upadacitinib was associated with an increased incidence of liver enzyme elevation compared to placebo.

Venous thromboembolismsEvents of deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients receiving JAK inhibitors, including upadacitinib. Upadacitinib should be used with caution in patients at high risk for DVT/PE.

Adverse reactionsThe most commonly reported adverse reactions in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis clinical trials (2% of patients in at least one of the indications) with upadacitinib 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, alanine transaminase increased, bronchitis, nausea, cough, aspartate transaminase increased, and hypercholesterolemia.

The most commonly reported adverse reactions in atopic dermatitis trials (2% of patients) with upadacitinib 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza.

Ankylosing spondylitis:Overall, the safety profile observed in patients with active ankylosing spondylitis treated with upadacitinib 15 mg was consistent with the safety profile observed in patients with RA.

Psoriatic arthritis:Overall, the safety profile observed in patients with active psoriatic arthritis treated with upadacitinib 15 mg was consistent with the safety profile observed in patients with RA. A higher incidence of acne and bronchitis was observed in patients treated with upadacitinib 15 mg (1.3% and 3.9%, respectively) compared to placebo (0.3% and 2.7%, respectively). A higher rate of serious infections (2.6 events per 100 patient-years and 1.3 events per 100 patient-years, respectively) and hepatic transaminase elevations (ALT elevations Grade 3 and higher rates 1.4% and 0.4%, respectively) was observed in patients treated with upadacitinib in combination with MTX therapy compared to patients treated with monotherapy. There was a higher rate of serious infections in patients 65 years of age, although data are limited.

Atopic dermatitis:Dose-dependent changes in ALT increased and/or AST increased ( 3 x ULN), lipid parameters, CPK values (> 5 x ULN), and neutropenia (ANC < 1 x 109 cells/L) associated with upadacitinib treatment were similar to what was observed in the rheumatologic disease clinical studies. Based on limited data in atopic dermatitis patients aged 65 years and older, there was a higher rate of overall adverse reactions with the upadacitinib 30 mg dose compared to the 15 mg dose. The safety profile for upadacitinib 15 mg in adolescents was similar to that in adults. The safety and efficacy of the 30 mg dose in adolescents are still being investigated.

This is not a complete summary of all safety information.

Please see the RINVOQ full SmPC for complete prescribing information at http://www.EMA.europa.eu.

Globally, prescribing information varies; refer to the individual country product label for complete information.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us atwww.abbvie.com. Follow @abbvie onTwitter,Facebook,LinkedInorInstagram.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2020 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References:

SOURCE AbbVie

abbvie.com

See the original post:
European Commission Approves RINVOQ (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with...

The European Union has evacuated the bulk of its diplomatic corps and local staff from Kabul but will keep a small "core team" on the ground to oversee the process until it's finally completed.

The majority of EU personnel, made up of diplomats, experts and administration officials with EU citizenship, has already left the country, the Commission confirmed on Thursday.

Some of them were personally welcomed last week by EU Commission President Ursula von der Leyen and European Council President Charles Michel at their arrival on the Torrejn Air Base, in Madrid.

A Commission spokesperson said a "core team" will remain stationed inside Kabul airport for the time being, although he didn't specify who was part of this entourage due to security reasons.

"[The core team] will be on the ground as long as necessary in order to complete the evacuation operations. And it's a very small core team," said spokesperson Peter Stano.

Additionally, the bloc has managed to evacuate over 400 members of the local staff, mainly Afghan nationals, who were working for the EU delegation in Kabul until the Taliban took over the country. This group includes employees and their family members.

Afghans who have worked or collaborated with Western governments are at high risk of being the target of reprisal and punishment by the Taliban.

The evacuated Afghan nationals are not legally entitled to stay and work inside the European Union and will have to be resettled across the bloc. But this reallocation won't be mandatory: it has to come through a voluntary offer from an EU country.

"[The Afghan nationals] are in the process of being transferred to member states who offered places. But we are still in ongoing contacts with the member states to make sure that there will be all of them taken care of," explained the spokesperson, without naming potential host countries.

"It's an ongoing process. It's a very intense process in which we are involved with the member states. But when it comes to EU local staff from Kabul, I think the member states are very clear that they are willing to help."

Evacuation efforts have accelerated in recent days as the US Administration of President Joe Biden refused to extend the withdrawal of troops beyond 31 August.

European countries have said that, without American support, it would be impossible to guarantee the safety of their citizens, many of whom flocked to the airport in search of an exit.

Countries like Belgium, Poland, Czech Republic, Germany and Canada have already completed the evacuation operations of their diplomatic staff. Others, like the United Kingdom and France, continue to work against the clock before the American departure.

Until this month, the EU's role in Afghanistan was mostly focused on promoting and strengthening democratic institutions, rule of law, governance, security and human rights. The EU Delegation in Kabul, which is headed by Ambassador Andreas von Brandt, also took part in the now-failed peace process between the Taliban and the Western-backed government of former President Ashraf Ghani.

Ambassador von Brandt took to Twitter on Thursday afternoon to announce he had "made it home" safely and thanked the French Air and Space Force for its assistance.

Despite the geopolitical defeat of the NATO alliance, Brussels says it will continue to provide humanitarian assistance to the vulnerable population of Afghanistan. On Tuesday, following a G7 virtual meeting, President von der Leyen announced a package of aid worth 200 million.

Since 1994, the EUs Civil Protection and Humanitarian Aid department (ECHO) has provided a total of 725.5 million to those affected by conflicts in Afghanistan.

Originally posted here:
EU completes evacuation of diplomatic staff from Kabul but keeps 'core team' on the ground - Euronews

To print this article, all you need is to be registered or login on Mondaq.com.

A wide range of new EU legislative measures on sustainablefinance came into force on 22 August 2021.

In total, there are five Commission Delegated Regulations andtwo Commission Delegated Directives (collectively the"Delegated Acts").

The Delegated Acts seek to integrate sustainability issues andconsiderations into the following EU legislative regimes

On 21 April 2021, the European Commission (the"Commission") published the draft texts of the DelegatedActs as part of its Sustainable Finance Package1.

Final versions of the Delegated Acts were published in the EUOfficial Journal on 2 August 2021.

The Delegated Acts are designed to complement the obligations inRegulation (EU) 2019/2088 ("SFDR") and Regulation (EU)2020/852 (the "Taxonomy Regulation") and form part of theCommission's 'ambitious and comprehensive' package ofmeasures to help improve the flow of money towards sustainableactivities across the EU.

UCITS

Commission Delegated Directive (EU) 2021/12702 (the"UCITS amending Directive") amends Directive 2010/43/EUand imposes obligations on UCITS management companies to:

AIFMD

Commission Delegated Regulation (EU) 2021/12553amends Delegated Regulation (EU) 231/2013 and imposes obligationson AIFMs to:

MiFID II

Commission Delegated Regulation (EU) 2021/12534amends Delegated Regulation (EU) 2017/565 and requires investmentfirms providing financial advice or portfolio management to carryout a mandatory assessment of the sustainability preferences ofclients; take this into account in the selection of financialproducts and prepare client reports explaining how therecommendation meets a client's investment objectives, riskprofile, capacity to bear loss and sustainability preferences.

Investments firm will also need to take into accountsustainability risks when complying with organisationalrequirements and to integrate sustainability into risk managementpolicies.

Commission Delegated Directive (EU) 2021/12695 amendsDelegated Directive (EU) 2017/593 (the "Amending MIFID ProductGovernance Directive") and will require investment firmsmanufacturing and distributing financial instruments to considersustainability factors in the product approval process of eachfinancial instrument and in the product governance and oversightarrangements for each financial instrument that is intended to bedistributed to clients seeking financial instruments with asustainability related profile.

Solvency II and the IDD

Commission Delegated Regulation (EU) 2021/12566amends Delegated Regulation (EU) 2015/35 and supplements SolvencyII to introduce the integration of sustainability risks in thegovernance, conflicts of interest and risk management of insuranceand reinsurance undertakings.

Commission Delegated Regulation (EU) 2021/12577amends Delegated Regulations (EU) 2017/2358 and (EU) 2017/2359 onthe integration of sustainability factors, risks and preferencesinto the product oversight and governance requirements forinsurance undertakings and insurance distributors and into therules on conduct of business and investment advice forinsurance-based investment products.

All the Delegated Acts entered into force on 22 August 2021.

The Delegated Regulations will be directly effective from 1August 20228 .

Member States have until 31 July 2022 to adopt and apply lawsimplementing the UCITS Amending Directive.

Member States have until 22 August 2022 to adopt laws toimplement the Amending MIFID Product Governance Directive. Thosemeasures must apply by 22 November 2022.

We have produced a guide9 focusing on sustainableinvestment fund strategies to help promote environmental, socialand governance aims.

1 https://ec.europa.eu/info/publications/210421-sustainable-finance-communication_en

2 https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32021L1270&from=EN

3 https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32021R1255&from=EN

4 https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32021R1253&from=EN

5 https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32021L1269&from=EN

6 https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32021R1256&from=EN

7 https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32021R1257&from=EN

8 Other than the correcting Delegated Regulation (EU)2021/1254 relating to MiFID.

9 https://maples.com/-/media/files/pdfs/esg/a-guide-to-sustainable-investment-funds.pdf

The content of this article is intended to provide a generalguide to the subject matter. Specialist advice should be soughtabout your specific circumstances.

POPULAR ARTICLES ON: Finance and Banking from European Union

Camilleri Preziosi Advocates

The term green loan' has become increasingly omnipresent in economic and market discourse. What is a green loan' and what distinguishes it from your typical loan'?

Finance Malta

With our 14th annual conference due to take place next week, preparations are in full swing and the deadline to register is fast approaching. Attendees at this year's hybrid event will be able to...

See the original post:
Sustainable Finance: New EU Delegated Legislation - Finance and Banking - European Union - Mondaq News Alerts